Cangrelor

DB06441

small molecule approved

Deskripsi

Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.

Struktur Molekul 2D

Berat 776.35
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The average elimination half-life of cangrelor is about 3-6 minutes.
Volume Distribusi In a study in healthy volunteers administration at a dose of 30 mcg/kg bolus plus 4 mcg/kg/min showed a volume of distribution of 3.9 L.
Klirens (Clearance) The mean clearance is about 43.2 L/h.

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Cangrelor is deactivated rapidly in the circulation by dephosphorylation to its primary metabolite, a nucleoside, which has negligible anti-platelet activity. Cangrelor's metabolism is independent of hepatic function and it does not interfere with other drugs metabolized by hepatic enzymes.

Rute Eliminasi

Following IV administration of 3H cangrelor, 58% of radioactivity was recovered in urine. The remaining 35% of radioactivity was in feces, presumably following biliary excretion.

Interaksi Makanan

1 Data
  • 1. Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.

Interaksi Obat

645 Data
Apixaban Apixaban may increase the anticoagulant activities of Cangrelor.
Dabigatran etexilate Dabigatran etexilate may increase the anticoagulant activities of Cangrelor.
Dasatinib The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Cangrelor.
Deferasirox The risk or severity of gastrointestinal bleeding can be increased when Cangrelor is combined with Deferasirox.
Edoxaban The risk or severity of bleeding can be increased when Edoxaban is combined with Cangrelor.
Ibrutinib The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Cangrelor.
Rivaroxaban Cangrelor may increase the anticoagulant activities of Rivaroxaban.
Sugammadex The risk or severity of bleeding and hemorrhage can be increased when Cangrelor is combined with Sugammadex.
Tibolone Tibolone may increase the anticoagulant activities of Cangrelor.
Urokinase Urokinase may increase the anticoagulant activities of Cangrelor.
Vorapaxar The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Cangrelor.
Ursodeoxycholic acid The risk or severity of adverse effects can be increased when Cangrelor is combined with Ursodeoxycholic acid.
Glycochenodeoxycholic Acid The risk or severity of adverse effects can be increased when Cangrelor is combined with Glycochenodeoxycholic Acid.
Cholic Acid The risk or severity of adverse effects can be increased when Cangrelor is combined with Cholic Acid.
Glycocholic acid The risk or severity of adverse effects can be increased when Cangrelor is combined with Glycocholic acid.
Deoxycholic acid The risk or severity of adverse effects can be increased when Cangrelor is combined with Deoxycholic acid.
Taurocholic acid The risk or severity of adverse effects can be increased when Cangrelor is combined with Taurocholic acid.
Obeticholic acid The risk or severity of adverse effects can be increased when Cangrelor is combined with Obeticholic acid.
Chenodeoxycholic acid The risk or severity of adverse effects can be increased when Cangrelor is combined with Chenodeoxycholic acid.
Taurochenodeoxycholic acid The risk or severity of adverse effects can be increased when Cangrelor is combined with Taurochenodeoxycholic acid.
Tauroursodeoxycholic acid The risk or severity of adverse effects can be increased when Cangrelor is combined with Tauroursodeoxycholic acid.
Bamet-UD2 The risk or severity of adverse effects can be increased when Cangrelor is combined with Bamet-UD2.
Dehydrocholic acid The risk or severity of adverse effects can be increased when Cangrelor is combined with Dehydrocholic acid.
Hyodeoxycholic Acid The risk or severity of adverse effects can be increased when Cangrelor is combined with Hyodeoxycholic Acid.
Glucosamine Glucosamine may increase the antiplatelet activities of Cangrelor.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Cangrelor is combined with Ibritumomab tiuxetan.
Obinutuzumab The risk or severity of adverse effects can be increased when Cangrelor is combined with Obinutuzumab.
Tipranavir Tipranavir may increase the antiplatelet activities of Cangrelor.
Vitamin E Vitamin E may increase the antiplatelet activities of Cangrelor.
Ginkgo biloba Ginkgo biloba may increase the anticoagulant activities of Cangrelor.
Ifosfamide The risk or severity of bleeding can be increased when Ifosfamide is combined with Cangrelor.
Quinine The therapeutic efficacy of Cangrelor can be increased when used in combination with Quinine.
Quinidine The therapeutic efficacy of Cangrelor can be increased when used in combination with Quinidine.
Tamoxifen The risk or severity of bleeding can be increased when Tamoxifen is combined with Cangrelor.
Toremifene The risk or severity of bleeding can be increased when Toremifene is combined with Cangrelor.
Clopidogrel Cangrelor may decrease the antiplatelet activities of Clopidogrel.
Pentoxifylline The therapeutic efficacy of Cangrelor can be increased when used in combination with Pentoxifylline.
Prasugrel Cangrelor may decrease the antiplatelet activities of Prasugrel.
Pentosan polysulfate The risk or severity of adverse effects can be increased when Pentosan polysulfate is combined with Cangrelor.
Levocarnitine The therapeutic efficacy of Cangrelor can be increased when used in combination with Levocarnitine.
Diethylstilbestrol Diethylstilbestrol may decrease the anticoagulant activities of Cangrelor.
Chlorotrianisene Chlorotrianisene may decrease the anticoagulant activities of Cangrelor.
Conjugated estrogens Conjugated estrogens may decrease the anticoagulant activities of Cangrelor.
Mestranol The risk or severity of adverse effects can be increased when Mestranol is combined with Cangrelor.
Estrone sulfate Estrone sulfate may decrease the anticoagulant activities of Cangrelor.
Quinestrol Quinestrol may decrease the anticoagulant activities of Cangrelor.
Hexestrol Hexestrol may decrease the anticoagulant activities of Cangrelor.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Cangrelor.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Cangrelor.
Polyestradiol phosphate Polyestradiol phosphate may decrease the anticoagulant activities of Cangrelor.
Esterified estrogens Esterified estrogens may decrease the anticoagulant activities of Cangrelor.
Zeranol Zeranol may decrease the anticoagulant activities of Cangrelor.
Equol Equol may decrease the anticoagulant activities of Cangrelor.
Methallenestril Methallenestril may decrease the anticoagulant activities of Cangrelor.
Epimestrol Epimestrol may decrease the anticoagulant activities of Cangrelor.
Moxestrol Moxestrol may decrease the anticoagulant activities of Cangrelor.
Estradiol acetate Estradiol acetate may decrease the anticoagulant activities of Cangrelor.
Estradiol benzoate Estradiol benzoate may decrease the anticoagulant activities of Cangrelor.
Estradiol cypionate Estradiol cypionate may decrease the anticoagulant activities of Cangrelor.
Estradiol valerate Estradiol valerate may decrease the anticoagulant activities of Cangrelor.
Biochanin A Biochanin A may decrease the anticoagulant activities of Cangrelor.
Formononetin Formononetin may decrease the anticoagulant activities of Cangrelor.
Estriol Estriol may decrease the anticoagulant activities of Cangrelor.
Limaprost The risk or severity of adverse effects can be increased when Limaprost is combined with Cangrelor.
Icosapent The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Cangrelor.
Mesalazine The risk or severity of bleeding can be increased when Mesalazine is combined with Cangrelor.
Indomethacin The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Cangrelor.
Nabumetone The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Cangrelor.
Ketorolac The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Cangrelor.
Tenoxicam The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Cangrelor.
Celecoxib The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Cangrelor.
Tolmetin The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Cangrelor.
Rofecoxib The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Cangrelor.
Piroxicam The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Cangrelor.
Fenoprofen The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Cangrelor.
Valdecoxib The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Cangrelor.
Diclofenac The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Cangrelor.
Sulindac The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Cangrelor.
Flurbiprofen The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Cangrelor.
Etodolac The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Cangrelor.
Mefenamic acid The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Cangrelor.
Naproxen The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Cangrelor.
Sulfasalazine The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Cangrelor.
Phenylbutazone The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Cangrelor.
Meloxicam The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Cangrelor.
Carprofen The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Cangrelor.
Diflunisal The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Cangrelor.
Salicylic acid The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Cangrelor.
Meclofenamic acid The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Cangrelor.
Oxaprozin The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Cangrelor.
Ketoprofen The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Cangrelor.
Balsalazide The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Cangrelor.
Olsalazine The risk or severity of bleeding can be increased when Olsalazine is combined with Cangrelor.
Lumiracoxib The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Cangrelor.
Magnesium salicylate The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Cangrelor.
Salsalate The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Cangrelor.
Choline magnesium trisalicylate The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Cangrelor.
Antrafenine The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Cangrelor.
Aminophenazone The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Cangrelor.
Antipyrine The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Cangrelor.

Target Protein

P2Y purinoceptor 12 P2RY12

Referensi & Sumber

Artikel (PubMed)
  • PMID: 26201463
    Keating GM: Cangrelor: A Review in Percutaneous Coronary Intervention. Drugs. 2015 Aug;75(12):1425-34. doi: 10.1007/s40265-015-0445-3.
  • PMID: 16595568
    Fugate SE, Cudd LA: Cangrelor for treatment of coronary thrombosis. Ann Pharmacother. 2006 May;40(5):925-30. Epub 2006 Apr 4.

Contoh Produk & Brand

Produk: 4 • International brands: 0
Produk
  • Kengreal
    Injection, powder, lyophilized, for solution • 50 mg/1 • Intravenous • US • Approved
  • Kengreal
    Injection, powder, lyophilized, for solution • 50 mg/1 • Intravenous • US • Approved
  • Kengrexal
    Powder, for solution • 50 mg / vial • Intravenous • Canada • Approved
  • Kengrexal
    Injection, powder, for solution • 50 mg • Intravenous • EU • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul